In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on Iovance Biotherapeutics (IOVA – Research Report), ...

Piper Sandler analyst Joseph Catanzaro lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $7.50 from $10 and keeps a Neutral ...

It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. The stock soared on news of ...

Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that ...

Truist Securities confirmed its positive stance on Iovance Biotherapeutics (NASDAQ:IOVA) shares, maintaining a Buy rating and a price target of $25.00. With the stock currently trading at $6.07, this ...

A Bay Area biotech is suing its insurance company to cover costs associated with patients allegedly injured during clinical ...

Technical analysis for Iovance Biotherapeutics Inc. IOVA including support levels resistance levels and stop losses for IOVA ...

In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted ...

In trading on Monday, shares of Iovance Biotherapeutics Inc (Symbol: IOVA) entered into oversold territory, hitting an RSI reading of 26.3, after changing hands as low as $5.91 per share.

Stifel maintains Buy on Iovance stock with $21 target On Monday, Stifel analysts maintained a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) with a steady price target of $21.00. According to ...